Phaseline

Targets › TROP-2

TROP-2: drug programs, companies and trials

1 program from 1 company in 44 trials: 24 Phase 2, 15 Phase 3, 5 Phase 1; Gastroenterology, Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on TROP-2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sichuan Baili PharmaceuticalBL-B01D1
Anti-TROP2 antibody-drug conjugate
TROP-2, TROP2, TACSTD2Phase 3Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer …Nov 2026

Conditions

Non-small Cell Lung Cancer (8) Urothelial Carcinoma (3) Breast Cancer (3) Small Cell Lung Cancer (2) Esophageal Squamous Cell Carcinoma (2) Extensive-stage Small-cell Lung Cancer (2) Cervical Cancer (2) Head and Neck Squamous Cell Carcinoma (2) Nasopharyngeal Carcinoma (1) Epithelial Ovarian Cancer (1) Triple-Negative Breast Cancer (1) HR+HER2- Breast Cancer (1)

Modalities

antibody (1)

Companies

Sichuan Baili Pharmaceutical (1)

Related targets

TROP2 (1) TACSTD2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.